Olaratumab (Lartruvo)

General information

Class/mechanism: Human IgG1 antibody that blocks the activity of platelet-derived growth factor receptor alpha (PDGFR-α). Olaratumab prevents binding of PDGF-AA and -BB ligands to PDGFR-α and blocks PDGF-AA, -BB, and -CC-induced receptor activation and downstream PDGFR-α pathway signaling, including the MAPK and PI3K pathways. PDGFR-α is a receptor tyrosine kinase expressed on mesenchymal origin cells, and signaling through PDGFR-α is involved in cell growth, chemotaxis, and mesenchymal stem cell differentiation.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Ewing's sarcoma
• Soft tissue sarcoma

Patient drug information

• Brief patient counseling information can be found in the Olaratumab (Lartruvo) package insert

History of changes in FDA indication

• 10/19/2016: FDA approved "for the treatment of patients with soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate."

Also known as

LY3012207, IMC-3G3, anti-PDGFR alpha monoclonal antibody IMC-3G3, anti-platelet-derived growth factor receptor alpha monoclonal antibody IMC-3G3